A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients
Conditions: Non-squamous Non-small Cell Lung Cancer Interventions: Drug: Adebrelimab + SHR-8068 + Pemetrexed + Carboplatin; Drug: Camrelizumab + Pemetrexed + Carboplatin; Drug: Adebrelimab + Pemetrexed + Carboplatin Sponsors: Shanghai Shengdi Pharmaceutical Co., Ltd Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Alimta | Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Research | Study